<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409383</url>
  </required_header>
  <id_info>
    <org_study_id>GM108</org_study_id>
    <nct_id>NCT00409383</nct_id>
  </id_info>
  <brief_title>Abraxane and Temodar Plus Genasense in Advanced Melanoma</brief_title>
  <official_title>A Pilot Study of Abraxane® (Albumin-bound Paclitaxel) and Temodar® (Temozolomide) Plus Genasense® (Oblimersen Sodium) in Subjects With Advanced Melanoma (&quot;The ATG Study&quot;).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genta Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genta Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, efficacy, pharmacokinetics, and
      pharmacodynamics of combination treatment with Temodar®, Genasense®, and Abraxane® in
      chemotherapy-naïve subjects with advanced melanoma and normal lactate dehydrogenase (LDH).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2006</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety based on adverse event reports and clinical laboratory findings</measure>
    <time_frame>During protocol therapy prior to the start of and during each cycle and up to 30 days after last dose of protocol therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (including rate of complete response)</measure>
    <time_frame>At the end of each cycle during protocol therapy, with follow-up every 2 months for up to 2 years from date of registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (including the rate of durable response)</measure>
    <time_frame>At the end of each cycle during protocol therapy, with follow-up every 2 months for up to 2 years from date of registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>At the end of each cycle during protocol therapy, with follow-up every 2 months for up to 2 years from date of registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of brain metastasis</measure>
    <time_frame>At the end of each cycle during protocol therapy, with follow-up every 2 months for up to 2 years from date of registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>12,15, and 18 months from date of registration, with follow-up every 2 months for up to 2 years from date of registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations of drug concentrations, intracellular Bcl-2 content, and response</measure>
    <time_frame>Cycle 1</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genasense® (oblimersen)</intervention_name>
    <description>Cohorts 1 and 2: Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 7 days (Week 1) and beginning again on Day 22 and continuing for 7 days (Week 4); Cohort 3: Genasense 900 mg as a 1-hour intravenous infusion on Day 1, 4, 8, and 11 (Weeks 1 and 2) and Day 22, 25, 29, and 32 (Weeks 4 and 5).</description>
    <other_name>G3139</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane® (paclitaxel protein-bound particles for injectable suspension)</intervention_name>
    <description>Cohorts 1 and 2: Abraxane 175 mg/m2 or 260 mg/m2 as a 30-minute intravenous infusion on Day 8 and Day 29 following end of Genasense continuous infusion; Cohort 3: Abraxane 175 mg/m2 as a 30-minute intravenous infusion on Day 4 and Day 25 following end of Genasense 1-hour infusion</description>
    <other_name>albumin-bound paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temodar® (temozolomide)</intervention_name>
    <description>Cohorts 1-3: Temodar 75 mg/m2/day orally on Days 1 through 42 (Week 1 through Week 6)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with progressive, unresectable, or advanced melanoma who are considered to be
             candidates for systemic treatment with chemotherapy

          -  Subjects will have measurable disease, an Eastern Cooperative Oncology Group
             Performance Status less than or equal to 2, and serum LDH less than or equal to 1.1
             times the upper limit of normal, but will not have previously received cytotoxic
             chemotherapy

          -  Prior immunotherapy, radiotherapy, or cytokine, biologic, or vaccine therapy is
             permitted in the adjuvant and/or metastatic setting

        Exclusion Criteria:

          -  Prior treatment with cytotoxic chemotherapy, including regional perfusion, or with
             Genasense®(oblimersen sodium)Injection

          -  Nonmeasurable disease only

          -  History or presence of brain metastasis or leptomeningeal disease

          -  Significant medical disease other than cancer

          -  Known human immunodeficiency virus infection

          -  Pregnant or lactating

          -  Known hypersensitivity to temozolomide, phosphorothioate-containing oligonucleotides,
             or products containing human albumin

          -  Use of any experimental therapy within 3 weeks prior to baseline evaluations, Other
             anticancer treatment (such as chemotherapy, radiation, or biologic or investigational
             therapies) while receiving therapy in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna C Pavlick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU MEDICAL CENTER</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2006</study_first_submitted>
  <study_first_submitted_qc>December 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2006</study_first_posted>
  <last_update_submitted>November 4, 2011</last_update_submitted>
  <last_update_submitted_qc>November 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Melanoma</keyword>
  <keyword>Normal baseline LDH</keyword>
  <keyword>Chemotherapy naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Oblimersen</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

